GSA Capital Partners’s Harvard Bioscience HBIO Stock Holding History

GSA Capital Partners’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16,844	Closed	-$95K	–	1903
2025 Q1	$95K	Buy	16,844 +14,023	+497%	+$180K	0.01%	1509
2024 Q4	$60K	Buy	2,821 +1,716	+155%	+$39.4K	﹤0.01%	1528
2024 Q3	$30K	Buy	+1,105	New	+$32.6K	﹤0.01%	1528
2023 Q2	–	Sell	-2,785	Closed	-$117K	–	1671
2023 Q1	$117K	Sell	2,785 -8,748	-76%	-$259K	0.01%	1335
2022 Q4	$319K	Buy	11,533 +3,751	+48%	+$92.4K	0.04%	893
2022 Q3	$199K	Buy	+7,782	New	+$257K	0.03%	1231
2021 Q1	–	Sell	-5,788	Closed	-$248K	–	1257
2020 Q4	$248K	Buy	5,788 +1,030	+22%	+$38.4K	0.04%	850
2020 Q3	$143K	Buy	+4,758	New	+$160K	0.02%	1076
2020 Q1	–	Sell	-1,600	Closed	-$49K	–	1253
2019 Q4	$49K	Sell	1,600 -50	-3%	-$1.44K	0.01%	1371
2019 Q3	$51K	Sell	1,650 -3,500	-68%	-$87K	0.01%	1325
2019 Q2	$103K	Sell	5,150 -12,866	-71%	-$377K	0.01%	1340
2019 Q1	$776K	Sell	18,016 -1,150	-6%	-$41.7K	0.08%	435
2018 Q4	$609K	Buy	19,166 +960	+5%	+$37.8K	0.07%	456
2018 Q3	$956K	Buy	18,206 +670	+4%	+$37.6K	0.05%	711
2018 Q2	$938K	Sell	17,536 -200	-1%	-$10.2K	0.05%	786
2018 Q1	$887K	Sell	17,736 -1,850	-9%	-$82.9K	0.05%	741
2017 Q4	$646K	Sell	19,586 -1,646	-8%	-$55.6K	0.04%	819
2017 Q3	$796K	Sell	21,232 -1,770	-8%	-$52.4K	0.05%	664
2017 Q2	$587K	Hold	23,002	–	–	0.04%	917
2017 Q1	$598K	Sell	23,002 -3,238	-12%	-$93.3K	0.03%	984
2016 Q4	$800K	Sell	26,240 -1,763	-6%	-$44.8K	0.05%	692
2016 Q3	$762K	Sell	28,003 -700	-2%	-$19.4K	0.04%	794
2016 Q2	$821K	Sell	28,703 -7,703	-21%	-$245K	0.05%	763
2016 Q1	$1.1M	Sell	36,406 -9,737	-21%	-$276K	0.07%	479
2015 Q4	$1.6M	Sell	46,143 -11,024	-19%	-$377K	0.08%	372
2015 Q3	$2.16M	Buy	57,167 +7,879	+16%	+$367K	0.11%	228
2015 Q2	$2.81M	Buy	49,288 +19,781	+67%	+$1.13M	0.11%	193
2015 Q1	$1.72M	Buy	29,507 +8,304	+39%	+$446K	0.07%	443
2014 Q4	$1.2M	Sell	21,203 -2,814	-12%	-$134K	0.08%	361
2014 Q3	$982K	Buy	24,017 +1,498	+7%	+$68.9K	0.05%	508
2014 Q2	$1.02M	Buy	22,519 +11,238	+100%	+$472K	0.05%	662
2014 Q1	$535K	Buy	11,281 +2,104	+23%	+$95.8K	0.04%	732
2013 Q4	$431K	Buy	9,177 +177	+2%	+$7.73K	0.03%	952
2013 Q3	$359K	Sell	9,000 -11,088	-55%	-$436K	0.03%	1016
2013 Q2	$716K	Buy	+20,088	New	+$769K	0.08%	354

Other funds holding HBIO

AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return

Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GSA Capital Partners's HBIO Position: Q2 2025 in Review

GSA Capital Partners sold out of Harvard Bioscience (HBIO) in Q2 2025, closing a stake of 16,844 shares — an estimated $95K sold.

GSA Capital Partners first reported a position in HBIO in Q2 2013 and held it in 35 quarters. The position peaked at $2.81M in Q2 2015. 68 funds tracked by Wall St. Rank hold HBIO as of Q2 2025.

GSA Capital Partners reported no remaining Harvard Bioscience position as of Q2 2025 after selling out during the quarter.
GSA Capital Partners sold 16,844 Harvard Bioscience shares in Q2 2025, an estimated $95K.
GSA Capital Partners first reported a position in Harvard Bioscience in Q2 2013 and held it in 35 quarters.
GSA Capital Partners's Harvard Bioscience position peaked at $2.81M in Q2 2015.
68 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.